Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-DXd and ICI in HR+/HER2-low Breast Cancer
NCT06733233Phase 2Not yet recruiting
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06733233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733233.